Scynexis Inc (SCYX)

$0.83 +0.08 (9.94%)
Market Cap 28.05M
Revenue (ttm) 3.75M
Net Income (ttm) -21.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 0.62
Profit Margin -567.73%
Debt to Equity Ratio 0.00
Volume 873,906
Avg Vol 514,536
Day's Range N/A - N/A
Shares Out 41.97M
Stochastic %K 90%
Beta 1.34
Analysts Strong Sell
Price Target $3.67

Company Profile

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to t...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 201 884 5485
Address:
1 Evertrust Plaza, 13th Floor, Jersey City, United States
DataJim
DataJim Jan. 23 at 7:56 PM
$SCYX Moving slowly, but moving in the right direction.
0 · Reply
DataJim
DataJim Jan. 23 at 7:55 PM
$SCYX There is movement on this.
0 · Reply
Aagshsg
Aagshsg Jan. 23 at 7:48 PM
$SCYX give us a buyout for $2!
0 · Reply
KwikStax
KwikStax Jan. 23 at 7:35 PM
$REVB Abandon ship and head over to $SCYX where we're actually trending up
0 · Reply
yft212
yft212 Jan. 23 at 7:19 PM
$SCYX Bought on a hunch a little while ago. Nice!
0 · Reply
XZeroDelta
XZeroDelta Jan. 23 at 6:55 PM
$SCYX Scynexis has impending Hansoh pharmeceutical sales in China this year which will trigger milestone and royalty payments. GSK will be in talks with the FDA this year to probably begin rolling out Brexafemme in the USA later this year or at the beginning of next year. Scynexis's current cash runway provides 2 years of operations. Have a great weekend!
1 · Reply
Aurum81
Aurum81 Jan. 23 at 6:51 PM
$SCYX
0 · Reply
SMARTR8
SMARTR8 Jan. 23 at 6:14 PM
$SCYX still holding majority of position 💎
0 · Reply
BioTechHealthX
BioTechHealthX Jan. 23 at 5:50 PM
$SCYX SCYNEXIS stock has a shrinking cash runway, collapsing revenue, and a burn rate that rivals its entire market cap. Here’s why NASDAQ: SCYX raises red flags for biotech investors. https://biotechhealthx.com/biotech-news/this-biotech-is-burning-cash-faster-than-its-market-value-scynexis-scyx/
1 · Reply
SMARTR8
SMARTR8 Jan. 23 at 4:58 PM
$SCYX x $OSRH Keep it going guys 🔥
0 · Reply
Latest News on SCYX
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Dec 22, 2025, 8:00 AM EST - 4 weeks ago

SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

Nov 19, 2025, 7:00 AM EST - 2 months ago

SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 5, 2025, 4:20 PM EST - 2 months ago

SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study

Oct 15, 2025, 8:00 AM EDT - 3 months ago

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

Sep 4, 2025, 8:30 AM EDT - 5 months ago

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 4:30 PM EDT - 5 months ago

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

May 28, 2025, 8:30 AM EDT - 8 months ago

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 5:08 PM EDT - 11 months ago

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 6, 2024, 4:30 PM EST - 1 year ago

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 10, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

Oct 3, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

Aug 27, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8, 2024, 4:30 PM EDT - 1 year ago

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

Jul 23, 2024, 7:00 AM EDT - 1 year ago

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 4:30 PM EDT - 1 year ago

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

Apr 30, 2024, 4:05 PM EDT - 1 year ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Apr 9, 2024, 4:05 PM EDT - 1 year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Scynexis: Update Following Restructuring Of GSK Deal

Apr 2, 2024, 10:04 AM EDT - 1 year ago

Scynexis: Update Following Restructuring Of GSK Deal

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 28, 2024, 4:01 PM EDT - 1 year ago

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

Jan 29, 2024, 5:15 PM EST - 2 years ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Jan 8, 2024, 4:00 AM EST - 2 years ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

Jan 5, 2024, 8:30 AM EST - 2 years ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

JANUARY 8 FINAL DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Jan 4, 2024, 7:00 AM EST - 2 years ago

JANUARY 8 FINAL DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with to Contact the Firm

Dec 29, 2023, 4:00 AM EST - 2 years ago

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with to Contact the Firm

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options

Dec 28, 2023, 9:00 AM EST - 2 years ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 22, 2023, 7:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Dec 21, 2023, 8:00 AM EST - 2 years ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 19, 2023, 5:30 AM EST - 2 years ago

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Scynexis: Stock Has Been Punished Enough: GSK Partnership, Future Revenue Potential And 2-Year Cash Runway Warrant A 'Buy'

Dec 18, 2023, 6:46 PM EST - 2 years ago

Scynexis: Stock Has Been Punished Enough: GSK Partnership, Future Revenue Potential And 2-Year Cash Runway Warrant A 'Buy'

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 18, 2023, 6:15 AM EST - 2 years ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 13, 2023, 7:00 AM EST - 2 years ago

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

IMPORTANT DEADLINE REMIDNER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 8, 2023, 5:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMIDNER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 6, 2023, 7:00 AM EST - 2 years ago

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Reminds Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 4, 2023, 7:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Reminds Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Dec 1, 2023, 6:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Scynexis To Contact Him Directly To Discuss Their Options

Nov 30, 2023, 8:30 AM EST - 2 years ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Scynexis To Contact Him Directly To Discuss Their Options

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 29, 2023, 7:50 PM EST - 2 years ago

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 22, 2023, 11:45 PM EST - 2 years ago

INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

IMPORTANT JANUARY DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 21, 2023, 7:00 AM EST - 2 years ago

IMPORTANT JANUARY DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 19, 2023, 11:45 PM EST - 2 years ago

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 17, 2023, 11:15 AM EST - 2 years ago

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

DataJim
DataJim Jan. 23 at 7:56 PM
$SCYX Moving slowly, but moving in the right direction.
0 · Reply
DataJim
DataJim Jan. 23 at 7:55 PM
$SCYX There is movement on this.
0 · Reply
Aagshsg
Aagshsg Jan. 23 at 7:48 PM
$SCYX give us a buyout for $2!
0 · Reply
KwikStax
KwikStax Jan. 23 at 7:35 PM
$REVB Abandon ship and head over to $SCYX where we're actually trending up
0 · Reply
yft212
yft212 Jan. 23 at 7:19 PM
$SCYX Bought on a hunch a little while ago. Nice!
0 · Reply
XZeroDelta
XZeroDelta Jan. 23 at 6:55 PM
$SCYX Scynexis has impending Hansoh pharmeceutical sales in China this year which will trigger milestone and royalty payments. GSK will be in talks with the FDA this year to probably begin rolling out Brexafemme in the USA later this year or at the beginning of next year. Scynexis's current cash runway provides 2 years of operations. Have a great weekend!
1 · Reply
Aurum81
Aurum81 Jan. 23 at 6:51 PM
$SCYX
0 · Reply
SMARTR8
SMARTR8 Jan. 23 at 6:14 PM
$SCYX still holding majority of position 💎
0 · Reply
BioTechHealthX
BioTechHealthX Jan. 23 at 5:50 PM
$SCYX SCYNEXIS stock has a shrinking cash runway, collapsing revenue, and a burn rate that rivals its entire market cap. Here’s why NASDAQ: SCYX raises red flags for biotech investors. https://biotechhealthx.com/biotech-news/this-biotech-is-burning-cash-faster-than-its-market-value-scynexis-scyx/
1 · Reply
SMARTR8
SMARTR8 Jan. 23 at 4:58 PM
$SCYX x $OSRH Keep it going guys 🔥
0 · Reply
SnapCrackleStop
SnapCrackleStop Jan. 23 at 3:18 PM
$SCYX Locked in. Overweight. $GSK has eyes 👀 on this one. Was a long wait but this is happening.. Huh? Yep. $$$
0 · Reply
StockScanners
StockScanners Jan. 23 at 3:49 AM
$SCYX keep watch if this holds above .74
0 · Reply
Constantine84
Constantine84 Jan. 22 at 9:50 PM
$SCYX done, crossed MA50 and close to MA200.
1 · Reply
SMARTR8
SMARTR8 Jan. 22 at 7:51 PM
$SCYX Loving it 💎🔥
1 · Reply
SPYmyQQQ
SPYmyQQQ Jan. 22 at 5:54 PM
🎯 Target Hit 🏁 📨 From Dec 10, 2025 💊 $SCYX 💵 Entry: $0.6400 ✅ Ext: $0.7514 💰 P/L: +17.41% 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
anan1
anan1 Jan. 22 at 5:27 PM
$SCYX Why this one is waking up? Should I buy or wait for some results
3 · Reply
Jimfuel100
Jimfuel100 Jan. 22 at 4:50 PM
$SCYX Way undervalued.
0 · Reply
schmitty999
schmitty999 Jan. 22 at 4:42 PM
$SCYX LETS ROLL
0 · Reply
SMARTR8
SMARTR8 Jan. 22 at 4:13 PM
Solid moves on $SCYX and $JAGX today 👌
0 · Reply
ImadogImaMut
ImadogImaMut Jan. 22 at 4:08 PM
$SCYX In Canada pharmacists do all the prescribing 💡
0 · Reply
LemuelPitkin
LemuelPitkin Jan. 22 at 4:00 PM
$SCYX Peter over at Yahoofin says there is a new Brexafemme product page....has anyone seen it? Please post link. Yahoo blocks that.
0 · Reply
Tfizzle
Tfizzle Jan. 22 at 3:45 PM
$SCYX heating up!
0 · Reply